首页> 外文期刊>臨床血液 >Critical pathway for the treatment of acute myelogenous leukemia
【24h】

Critical pathway for the treatment of acute myelogenous leukemia

机译:治疗急性髓性白血病的关键途径

获取原文
获取原文并翻译 | 示例
       

摘要

Based on analysis of data from 10 patients newly diagnosed as having acute myelogenous leukemia (AML), we developed a critical pathway (CP) to prevent infection and thus shorten the period of hospitalization. This CP shows laboratory test results, vital signs, chemotherapy regimen, concomitant supportive care and oral medications, gargling with antiseptic mouthwash, other anti-infection measures, diet, room conditions, patient education in anti-infection measures, outcome, and variance on the vertical axis and time on the horizontal axis. After introduction of the CP, 9 of the newly diagnosed AML patients did not experience severe treatment-related complications during a mean hospitalization of 29 days until remission and 95 days until discharge. These results suggest that the present CP makes it possible to shorten the hospital stay, reduce treatment costs, and improve the quality of life of AML patients.
机译:基于10名新诊断为急性髓性白血病(AML)的10例患者的数据分析,我们开发了一种关键途径(CP),以防止感染,从而缩短住院时间。 本CP显示实验室测试结果,生命体征,化疗方案,伴随的支持性护理和口服药物,用防腐漱口水,其他抗感染措施,饮食,房间条件,患者教育,抗菌措施,结果和方差 垂直轴和水平轴上的时间。 在引入CP后,新诊断的AML患者中的9例在29天的平均住院期间没有经历严重的治疗相关并发症,直至缓解和95天直至排放。 这些结果表明,本CP可以缩短住院住院,降低治疗成本,提高AML患者的生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号